KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $570,000.

  • Neogenomics' Free Cash Flow rose 136.70% to $570,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.0 million, marking a year-over-year increase of 20.75%. This contributed to the annual value of -$34.0 million for FY2024, which is 10.85% down from last year.
  • Neogenomics' Free Cash Flow amounted to $570,000 in Q3 2025, which was down 95.93% from $14.0 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Free Cash Flow registered a high of $14.0 million during Q2 2025, and its lowest value of -$37.3 million during Q1 2022.
  • Over the past 3 years, Neogenomics' median Free Cash Flow value was -$1.8 million (recorded in 2024), while the average stood at -$7.3 million.
  • Per our database at Business Quant, Neogenomics' Free Cash Flow slumped by 623.19% in 2021 and then surged by 1,620.76% in 2025.
  • Over the past 5 years, Neogenomics' Free Cash Flow (Quarterly) stood at -$31.8 million in 2021, then soared by 74.12% to -$8.2 million in 2022, then skyrocketed by 230.51% to $10.7 million in 2023, then slumped by 116.77% to -$1.8 million in 2024, then spiked by 136.70% to $570,000 in 2025.
  • Its Free Cash Flow was $570,000 in Q3 2025, compared to $14.0 million in Q2 2025 and -$29.8 million in Q1 2025.